SCHEMBL23218662

SCHEMBL23218662

CCOC(=O)Cc1ccccc1OCc1coc2c(NCC(C)C)cc(Cl)cc12

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.36
TP53 P04637 1/20 0.36
THRB P10828 1/20 0.36
TBXAS1 P24557 1/20 0.36
PTGDR2 Q9Y5Y4 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
MASP2 O00187 1/20 0.34
F2 P00734 1/20 0.34
CFD P00746 1/20 0.34
NPC1 O15118 1/20 0.33
MEN1 O00255 3/20 0.33
KMT2A Q03164 3/20 0.33
ALDH1A1 P00352 3/20 0.33
LMNA P02545 3/20 0.33
RECQL P46063 1/20 0.33
POLB P06746 1/20 0.33
KDM4E B2RXH2 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
GAA P10253 2/20 0.32
HPGD P15428 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29852451 1.00 MAPT (0.36) MAPTTP53THRBTBXAS1PTGDR2
SCHEMBL29853049 0.91 MAPT (0.38) MAPTTP53THRBTBXAS1PTGDR2
SCHEMBL29591621 0.91 MAPT (0.38) MAPTTP53THRBTBXAS1PTGDR2
SCHEMBL23218123 0.91 MAPT (0.38) MAPTTP53THRBTBXAS1PTGDR2
SCHEMBL29852505 0.90 MAPT (0.37) MAPTTP53THRBTBXAS1PTGDR2
SCHEMBL23218481 0.90 MAPT (0.37) MAPTTP53THRBTBXAS1PTGDR2
SCHEMBL29591612 0.90 MAPT (0.37) MAPTTP53THRBTBXAS1PTGDR2
SCHEMBL23219020 0.88 PTGS2 (0.36) MAPTTP53THRBALDH1A1LMNA
SCHEMBL29852781 0.88 PTGS2 (0.36) MAPTTP53THRBALDH1A1LMNA
SCHEMBL23218319 0.88 MAPT (0.39) MAPTTP53THRBTBXAS1PTGDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 EP disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB MAPT 4793/4885TP53 3891/4885THRB 2013/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB MAPT 3561/4885TP53 3580/4885THRB 3892/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.